Caribou Biosciences Stock Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy CRBU?
Source: Yahoo Finance
- Market Volatility: Caribou Biosciences (CRBU) is listed among the 7 most volatile stocks under $5 for day trading, indicating significant investor interest and potential short-term trading opportunities in this low-priced stock segment.
- Sales Potential Forecast: Clear Street projects that Caribou's CB-011 may reach peak sales of $734 million by 2040, despite a low 20% chance of success, highlighting the balance of market potential against clinical risks.
- Rating and Price Target: On February 2, 2026, Clear Street initiated coverage of Caribou with a 'Buy' rating and a $13 price target, primarily based on its upcoming CAR-T program, reflecting market confidence in the company's future developments.
- Industry Dynamics: On January 6, 2026, BofA lowered Caribou's price target from $8 to $6 while maintaining a 'Buy' rating, indicating concerns over durability amidst a broader reset in U.S. biopharma valuations, which may affect investor sentiment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRBU?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRBU
Wall Street analysts forecast CRBU stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.970
Low
6.00
Averages
8.00
High
10.00
Current: 1.970
Low
6.00
Averages
8.00
High
10.00
About CRBU
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company engaged in developing transformative therapies for patients with devastating diseases. The Company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against disease. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T platform to offer broad access and rapid availability of treatments for patients with hematologic malignancies and autoimmune diseases. Its genome-editing platform, including its novel chRDNA technology, enables more precise genome editing of allogeneic cell therapies. It is advancing its pipeline of allogeneic CAR-T cell therapies with clinical development programs targeting the treatment of hematologic malignancies and autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Caribou Bioscience Q4 Earnings Beat Expectations
- Earnings Highlights: Caribou Bioscience reported a Q4 GAAP EPS of -$0.28, beating expectations by $0.04, indicating an improvement in profitability despite still being in the red.
- Revenue Surge: The company achieved Q4 revenue of $3.94M, representing an 89.4% year-over-year increase and surpassing market expectations by $1.98M, reflecting strong product demand and enhanced market acceptance.
- Cash Position: As of December 31, 2025, Caribou reported $142.8 million in cash, cash equivalents, and marketable securities, down from $249.4 million in 2024, highlighting challenges in cash management.
- Future Outlook: Caribou expects its current cash reserves to fund its operational plans, including dose expansion for CB-011 and startup activities for the planned vispa-cel pivotal trial, projected to last into the second half of 2027, demonstrating confidence in future growth.
See More
Vir Biotechnology Reports Better-Than-Expected Quarterly Loss
- Earnings Surprise: Vir Biotechnology reported a quarterly loss of $0.31 per share, better than the Zacks consensus estimate of a $0.42 loss, indicating improvements in cost management despite ongoing challenges.
- Significant Revenue Growth: The company posted revenues of $64.07 million for the quarter, surpassing the Zacks consensus estimate by 243.23%, compared to $12.37 million a year ago, demonstrating positive progress in market demand recovery.
- Stock Performance: Since the beginning of the year, Vir Biotechnology's shares have risen approximately 25.4%, significantly outperforming the S&P 500's gain of 0.9%, reflecting investor confidence in the company's future growth potential.
- Future Outlook: Although the current EPS estimate stands at -$0.60 with revenues of $2.41 million, the industry rank is in the top 37% of over 250 Zacks industries, indicating a generally positive trend that may support stock performance.
See More
Caribou Biosciences Stock Analysis
- Market Volatility: Caribou Biosciences (CRBU) is listed among the 7 most volatile stocks under $5 for day trading, indicating significant investor interest and potential short-term trading opportunities in this low-priced stock segment.
- Sales Potential Forecast: Clear Street projects that Caribou's CB-011 may reach peak sales of $734 million by 2040, despite a low 20% chance of success, highlighting the balance of market potential against clinical risks.
- Rating and Price Target: On February 2, 2026, Clear Street initiated coverage of Caribou with a 'Buy' rating and a $13 price target, primarily based on its upcoming CAR-T program, reflecting market confidence in the company's future developments.
- Industry Dynamics: On January 6, 2026, BofA lowered Caribou's price target from $8 to $6 while maintaining a 'Buy' rating, indicating concerns over durability amidst a broader reset in U.S. biopharma valuations, which may affect investor sentiment.
See More
Clear Street Initiates Buy on Caribou Biosciences, Sees 790% Upside
- Buy Rating Initiated: Clear Street has initiated coverage on Caribou Biosciences (CRBU) with a buy rating, citing the company's promising pipeline of off-the-shelf CAR-T therapies for cancer, which has led to a ~6% increase in shares during Tuesday trading.
- Price Target Set: The firm has set a price target of $13, representing approximately 790% upside based on the February 2 close, reflecting strong confidence in the company's future performance.
- Product Competitiveness: Analyst Bill Maughan noted that Caribou's candidates
See More
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
- Market Potential: The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034, reflecting the rapid rise of precision therapies and immunotherapies, enhancing the investment outlook for companies like GT Biopharma.
- Clinical Trial Progress: GT Biopharma has advanced its GTB-3650 clinical trial to Cohort 4, where patients receive a dosing of 10μg/kg/day, indicating potential efficacy in treating resistant blood cancers and providing new treatment options for patients.
- Safety Confirmation: Six patients enrolled in Cohorts 1, 2, and 3 have successfully completed GTB-3650 treatment, establishing its safety profile with no dose-limiting toxicities observed across all completed cohorts, thereby boosting confidence in the clinical trial.
- Future Outlook: GT Biopharma plans to share its next trial update in Q1 2026, with expectations to continue assessing higher doses for efficacy, further driving innovation in the field of tumor immunotherapy.
See More
Caribou Biosciences Hosts Panel on vispa-cel to Broaden Patient Access for CAR-T Therapy
- Expert Panel Discussion: Caribou Biosciences will host a panel on December 6, 2025, to discuss how vispa-cel can promote CAR-T therapy in community hospitals, thereby expanding patient access and enhancing the company's influence in oncology treatment.
- Clinical Trial Progress: As of September 2025, 84 patients have been treated in the ANTLER trial, demonstrating that vispa-cel's safety and efficacy are comparable to autologous CAR-T therapies, which is expected to bolster the company's competitive position in the market.
- Innovative Treatment Approach: Vispa-cel is the first allogeneic CAR-T therapy in clinical use with a PD-1 knockout, aimed at improving therapeutic efficacy, potentially transforming the treatment landscape for patients with large B-cell lymphoma and increasing market appeal for the company's products.
- Regulatory Recognition: The FDA has granted vispa-cel several key designations, including Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug status, further enhancing its market potential and investment attractiveness.
See More
Caribou Bioscience Q4 Earnings Beat Expectations
- Earnings Highlights: Caribou Bioscience reported a Q4 GAAP EPS of -$0.28, beating expectations by $0.04, indicating an improvement in profitability despite still being in the red.
- Revenue Surge: The company achieved Q4 revenue of $3.94M, representing an 89.4% year-over-year increase and surpassing market expectations by $1.98M, reflecting strong product demand and enhanced market acceptance.
- Cash Position: As of December 31, 2025, Caribou reported $142.8 million in cash, cash equivalents, and marketable securities, down from $249.4 million in 2024, highlighting challenges in cash management.
- Future Outlook: Caribou expects its current cash reserves to fund its operational plans, including dose expansion for CB-011 and startup activities for the planned vispa-cel pivotal trial, projected to last into the second half of 2027, demonstrating confidence in future growth.
See More
Vir Biotechnology Reports Better-Than-Expected Quarterly Loss
- Earnings Surprise: Vir Biotechnology reported a quarterly loss of $0.31 per share, better than the Zacks consensus estimate of a $0.42 loss, indicating improvements in cost management despite ongoing challenges.
- Significant Revenue Growth: The company posted revenues of $64.07 million for the quarter, surpassing the Zacks consensus estimate by 243.23%, compared to $12.37 million a year ago, demonstrating positive progress in market demand recovery.
- Stock Performance: Since the beginning of the year, Vir Biotechnology's shares have risen approximately 25.4%, significantly outperforming the S&P 500's gain of 0.9%, reflecting investor confidence in the company's future growth potential.
- Future Outlook: Although the current EPS estimate stands at -$0.60 with revenues of $2.41 million, the industry rank is in the top 37% of over 250 Zacks industries, indicating a generally positive trend that may support stock performance.
See More
Caribou Biosciences Stock Analysis
- Market Volatility: Caribou Biosciences (CRBU) is listed among the 7 most volatile stocks under $5 for day trading, indicating significant investor interest and potential short-term trading opportunities in this low-priced stock segment.
- Sales Potential Forecast: Clear Street projects that Caribou's CB-011 may reach peak sales of $734 million by 2040, despite a low 20% chance of success, highlighting the balance of market potential against clinical risks.
- Rating and Price Target: On February 2, 2026, Clear Street initiated coverage of Caribou with a 'Buy' rating and a $13 price target, primarily based on its upcoming CAR-T program, reflecting market confidence in the company's future developments.
- Industry Dynamics: On January 6, 2026, BofA lowered Caribou's price target from $8 to $6 while maintaining a 'Buy' rating, indicating concerns over durability amidst a broader reset in U.S. biopharma valuations, which may affect investor sentiment.
See More
Clear Street Initiates Buy on Caribou Biosciences, Sees 790% Upside
- Buy Rating Initiated: Clear Street has initiated coverage on Caribou Biosciences (CRBU) with a buy rating, citing the company's promising pipeline of off-the-shelf CAR-T therapies for cancer, which has led to a ~6% increase in shares during Tuesday trading.
- Price Target Set: The firm has set a price target of $13, representing approximately 790% upside based on the February 2 close, reflecting strong confidence in the company's future performance.
- Product Competitiveness: Analyst Bill Maughan noted that Caribou's candidates
See More
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
- Market Potential: The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034, reflecting the rapid rise of precision therapies and immunotherapies, enhancing the investment outlook for companies like GT Biopharma.
- Clinical Trial Progress: GT Biopharma has advanced its GTB-3650 clinical trial to Cohort 4, where patients receive a dosing of 10μg/kg/day, indicating potential efficacy in treating resistant blood cancers and providing new treatment options for patients.
- Safety Confirmation: Six patients enrolled in Cohorts 1, 2, and 3 have successfully completed GTB-3650 treatment, establishing its safety profile with no dose-limiting toxicities observed across all completed cohorts, thereby boosting confidence in the clinical trial.
- Future Outlook: GT Biopharma plans to share its next trial update in Q1 2026, with expectations to continue assessing higher doses for efficacy, further driving innovation in the field of tumor immunotherapy.
See More
Caribou Biosciences Hosts Panel on vispa-cel to Broaden Patient Access for CAR-T Therapy
- Expert Panel Discussion: Caribou Biosciences will host a panel on December 6, 2025, to discuss how vispa-cel can promote CAR-T therapy in community hospitals, thereby expanding patient access and enhancing the company's influence in oncology treatment.
- Clinical Trial Progress: As of September 2025, 84 patients have been treated in the ANTLER trial, demonstrating that vispa-cel's safety and efficacy are comparable to autologous CAR-T therapies, which is expected to bolster the company's competitive position in the market.
- Innovative Treatment Approach: Vispa-cel is the first allogeneic CAR-T therapy in clinical use with a PD-1 knockout, aimed at improving therapeutic efficacy, potentially transforming the treatment landscape for patients with large B-cell lymphoma and increasing market appeal for the company's products.
- Regulatory Recognition: The FDA has granted vispa-cel several key designations, including Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug status, further enhancing its market potential and investment attractiveness.
See More
